ROS as a novel indicator to predict anticancer drug efficacy

Area of Science:

• Mitochondrial biology
• Cancer therapeutics
• Oxidative stress

Background:

• Mitochondria are key sites for reactive oxygen species (ROS) generation.
• Elevated ROS levels in cancer cells with mitochondrial genetic abnormalities can induce apoptosis.
• Targeting mitochondria to stimulate ROS offers a potential cancer-specific therapy approach.

Purpose of the Study:

• To investigate the influence of baseline reactive oxygen species (ROS) levels on cancer cell response to ROS-stimulating therapy.
• To evaluate the efficacy of mitochondria-targeting agents in combination with conventional chemotherapy.

Main Methods:

• Utilized four cancer and one normal cell line treated with cisplatin and dequalinium chloride hydrate.
• Assessed cell viability, combination index (CI), mitochondrial DNA copy number (mtDNAcn), ROS levels, and mitochondrial membrane potential (MMP).
• Investigated gene and protein expression in ROS-mediated apoptosis pathways.

Main Results:

• A correlation was found between baseline ROS levels, mtDNAcn, and drug sensitivity.
• Synergistic effects were observed when combining the drugs, with ROS playing a crucial role in cell death.
• Baseline ROS levels influenced cancer cell sensitivity to the therapeutic agents.

Conclusions:

• Mitochondria-targeting therapy shows promise for enhanced efficacy over conventional treatments.
• Cancer cells with lower baseline ROS may be more sensitive to this therapy, while high ROS cells might be more resistant.
• Further in vivo studies are needed, but findings offer insights into developing novel anticancer therapeutic strategies.